A Big Beat, ZYN Ultra Lands, and the Round-Trip Back to All-Time Highs: Downgrading to Hold at ~23x

Results vs. Consensus

Q2 2026 Scorecard

Segment Scorecard

Operating Companies Income (OCI) is now reported at the business-unit level (International and U.S.), not by segment. International adjusted OCI grew +15.5% reported (+13.2% organic) to $4,642M; U.S. adjusted OCI was $279M (-20.8% reported, -19.1% organic) but nearly tripled sequentially off Q1's depressed base. Total PMI adjusted OCI was $4,921M (+12.6% reported, +10.6% organic).

Quality of Beat

Revenue: Group organic growth of +7.6% is a sharp reacceleration from Q1's +2.7% and comfortably ahead of the consensus revenue line. The composition is healthier than the headline mix suggests: International Smoke-Free grew +11.8% organic, International Combustibles delivered a surprising +6.4% on near-double-digit pricing and, for once, growing volume, and the U.S. drag shrank to essentially nil (-0.9% organic) from Q1's -31.6% collapse. This was a genuinely broad quarter, not a single-segment carry.

Margins & OI: Adjusted operating margin expanded 0.7pp to 42.6%, driven by gross-margin gains (pricing, favorable smoke-free mix, scale, and manufacturing productivity, with over $300M of gross cost savings booked in H1 toward the $2B 2024–2026 target). Reported operating income rose a headline +22.0% because the prior-year base carried restructuring and a goodwill impairment that did not repeat; the cleaner organic OI growth of +10.7% is the number that matters, and it is above the full-year algorithm.

EPS: The adjusted-EPS beat is high-quality but not entirely operational. Of the outperformance versus the company's own prior forecast, management attributed roughly one-third to a transactional currency benefit (an unrealized effect on a deferred tax liability tied to a weaker Russian ruble) and two-thirds to a combination of SG&A phasing into Q3 and the combustible strength. The 3-cent net FX tailwind is small; ex-currency growth of +13.6% is the real figure, and it is excellent. Reported EPS of $1.80 fell 7.7% purely on the non-cash RBH impairment, which is excluded from adjusted results and reflects a lower carrying value on PMI's deconsolidated Canadian affiliate, not a change in the operating business.

Segment Performance

International Smoke-Free — Still the Engine, Just in a Noisy Gear

The segment that drives most of PMI's value grew net revenue +14.2% (+11.8% organic) on +8.0% volume growth, with adjusted gross profit +17.1% (+14.6% organic) and a segment gross margin of 70.1% (+1.8pp). The deceleration from Q1's +15.8% organic is real but well-understood: IQOS HTU adjusted IMS grew +5.1% against expected transitory headwinds in Japan (post-excise pantry de-load) and the characterizing-flavor bans in Poland and Hungary. Strip those out and adjusted IMS grew +10.2% in the quarter and over +11% for H1, "consistent with recent history." IQOS held roughly 76% of the global heat-not-burn category and, notably, entered Kantar's list of the top 100 most valuable global brands for the first time. VEEV (e-vapor) shipments grew +55.1% and it is now the clear number-one closed-pod brand in Europe; international ZYN volumes grew +32% excluding the Nordics.

"IQOS adjusted in-market sales volume increased by +5%, including expected transitory headwinds from the April excise increase in Japan and the characterizing flavor ban in Poland. Excluding these two markets, double-digit growth continued, reflecting the broad-based strengths of our Smoke-Free Products business across markets." — Emmanuel Babeau, outgoing Group CFO

Assessment: The underlying franchise is intact; the headline is just carrying two temporary weights. The ~+10% ex-Japan/Poland IMS, the 70%+ gross margin, the ~76% category share, and the VEEV and international-ZYN momentum all say the compounding engine is unchanged. What has changed is the near-term optics: with Japan digesting a second excise step in October, the reported IMS number will stay noisy through year-end. That is a modeling nuisance, not a thesis threat, but it removes the clean "accelerating" narrative that helped justify the April upgrade.

U.S. — The Sequential Recovery and the ZYN Ultra Launch

After Q1's operating loss, the U.S. staged the recovery management promised: net revenue rose +38% and adjusted gross profit +46% sequentially, and adjusted OCI swung to a $279M profit. On a year-on-year basis, segment net revenue was essentially flat (-0.9% organic), with broadly stable ZYN revenues offset by declines in cigars and unfavorable phasing in the Aspeya wellness business. ZYN shipments returned to +1.8% growth (to 2.9 billion pouches) even against a prior-year inventory tailwind, and the headline event was the June launch of ZYN Ultra (9mg and 11mg moist variants, priced below the flagship dry range to close the strength-and-price gap) plus additional dry flavors, with 1.5mg and 8mg dry formats due in Q3. Gross margin fell 6.0pp to 65.4% on higher manufacturing costs from the new Colorado capacity ramp, which reached full commercial production in July. ZYN remains the clear premium leader at roughly a 57% retail value share.

"In the U.S., we posted a significant sequential improvement in net revenues, gross profit, and operating company income compared to a challenging Q1. ZYN offtake volumes were broadly stable to slightly growing versus the prior year, reflecting the uneven competitive landscape described in recent quarters." — Emmanuel Babeau, outgoing Group CFO

Assessment: This is the most important favorable development in the print and the direct answer to the dominant risk we flagged in April. The catalyst that was "optionality we are not paying full price for" has arrived: ZYN Ultra shipped, the MRTP authorization landed, and the portfolio gap is being closed on schedule rather than slipping past 2026. The honest caveat is that offtake is still only flat to slightly growing, the reacceleration is two weeks old, and management is deliberately spending H2 margin to press the launch. So the risk is healing, not resolved. The direction is right; the magnitude is unproven.

International Combustibles — An Exceptional Quarter Management Says Won't Repeat

Combustibles delivered the surprise of the quarter: net revenue +9.8% (+6.4% organic) on pricing of nearly +10%, with cigarette volume actually growing +1.1% (led by Turkey, Indonesia, and Egypt, markets where smoke-free products are banned or tiny), and adjusted gross profit +11.5% (+8.0% organic). PMI held category volume share at 25.3%, and Marlboro gained 0.3pp to match its record 11.0% share. Management was explicit that this pace is not sustainable: it now guides full-year pricing above +7% (up from prior), but expects the benefit to be largely offset by adverse geographic mix as volume skews toward lower-revenue-per-unit markets, and it does not expect the Q2 volume outperformance to repeat at the same magnitude.

"Our combustible performance was above our expectation in an especially strong quarter, with growing volumes, very good pricing, stable category share, and gross profit growth. While we do not expect this delivery to be repeated to the same magnitude for the full year, such results demonstrate the robustness of our portfolio." — Emmanuel Babeau, outgoing Group CFO

Assessment: The cash engine over-delivered, and it is worth being precise about why that is a double-edged read. It is a genuine positive: growing combustible volume and near-double-digit pricing funded the smoke-free investment and lifted the whole quarter. But it is also the lower-quality half of the beat, structurally concentrated in demographically-young, smoke-free-banned markets, and management has pre-warned that it fades. Investors extrapolating the +1.1% volume and +10% pricing into 2027 will be disappointed; this was a high-water mark, not a new run-rate.

IQOS by Geography

Key Topics & Management Commentary

Overall Management Tone: Confident and, on the U.S., overtly enthusiastic for the first time in the coverage period, with the outgoing CFO describing "an alignment of planets" behind ZYN and a plan to "go 360" on investment. Management was careful to frame the international smoke-free deceleration as pre-flagged Japan and Poland noise rather than a demand problem, and equally careful to pre-warn that the combustible over-delivery will not repeat. The posture was that of a team choosing to reinvest a strong first half rather than bank it as guidance upside, which is credible but also removes the beat-and-raise the multiple might have wanted at these levels.

1. ZYN Ultra Lands and the "Alignment of Planets" in the U.S.

The defining development of the quarter is that the U.S. plan came together on schedule. ZYN Ultra shipped in June, the FDA granted MRTP status to 20 ZYN variants on June 30, a new brand campaign ("When it Clicks") is rolling out, and 1.5mg and 8mg dry variants follow in Q3. After several quarters of framing ZYN's portfolio gap as an FDA-gated constraint it could not control, management now has the product, the regulatory clearance, and the marketing in hand at once, and it is choosing to spend aggressively behind them in H2.

"We have an alignment of planets that is, of course, great. We have a much broader portfolio of variants... we are coming with now ZYN Ultra... On top of that, we have our new marketing campaign, When it Clicks. The MRTP is almost coming as an icing on the cake. That's really a great moment in the U.S. to accelerate. We're going to go 360." — Emmanuel Babeau, outgoing Group CFO

Assessment: This is exactly the resolution path we sketched in April, delivered a quarter early. It converts the ZYN thesis from "wait on an unforecastable FDA decision" to "execute a launch that is already underway," which materially de-risks the single biggest concern in the story. The catch for the stock is that this good news is now known, the offtake proof will take another quarter or two, and the cost is an explicit H2 investment step-up that is precisely why the operational guide did not go up despite two beats.

2. The First-Ever Nicotine-Pouch MRTP

On June 30 the FDA authorized 20 flagship ZYN variants as Modified Risk Tobacco Products, the first and only such designation for a nicotine pouch. It allows PMI to market a specific reduced-risk claim relative to cigarettes, a meaningful differentiator in a category increasingly crowded with unauthorized and synthetic-nicotine competitors.

"We also believe ZYN is well-positioned from a regulatory standpoint, notably following the modified risk tobacco product authorization of 20 SKUs, making it the only nicotine pouch product with the designation and allowing us to market the claim, 'Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.'" — Emmanuel Babeau, outgoing Group CFO

Assessment: The MRTP is a durable competitive moat more than a near-term volume driver. It hands ZYN a science-and-regulation credential no competitor holds, strengthens the case against future flavor or strength restrictions, and supports the premium positioning. It will not move Q3 offtake, but it lowers the long-run regulatory tail risk that has always shadowed the U.S. nicotine-pouch bull case.

3. International Smoke-Free Moderates on Japan and Poland

The engine's deceleration to +11.8% organic revenue and +5.1% IMS is entirely explained by two known headwinds: Japan's post-April-excise pantry de-load and the Poland and Hungary characterizing-flavor bans. Excluding Japan and Poland, IMS grew +10.2% in Q2 and over +11% in H1. Management also flagged a phasing quirk that flatters H1: HTU shipments ran above in-market sales in the first half and should reverse in H2 (IMS a bit above shipments), a headwind to reported H2 smoke-free revenue growth.

Assessment: The moderation is optical and reversible, but it matters for the multiple. Part of the April Outperform rested on the segment "accelerating," and it is no longer doing so on a reported basis; it is holding a healthy underlying pace while two transient bans and an excise digestion wash through. That distinction is analytically correct and commercially fine, but it takes away the clean acceleration narrative just as the stock reaches its highs.

4. Japan: The Biggest Excise Step Is Behind, October Is Smaller, 2027 Turns Favorable

Japan HTU adjusted IMS fell 3.4% (about +1% excluding the pantry de-load) as consumers absorbed the largest HTU price increase in the market's history (roughly JPY 40, about a 10% increase for IQOS, with no change to cigarette excise). IQOS held category share in the high-60s and recovered through the quarter to essentially match Q1's monthly volume ex-pantry. Management sees more volatility around the October second step but flagged that its pass-on then is smaller (closer to JPY 20), and that the 2027–2029 excise plan is more gradual (about JPY 12/year) and, crucially, applies equally to cigarettes and heat-not-burn.

"We've gone through the worst for us, because this first increase was the worst... In 2027, there is already a plan, three years of excise duty increase at a much more limited level, but both equally for CC and for heat-not-burn... That is creating a window to increase price, which was not always obvious in the past." — Emmanuel Babeau, outgoing Group CFO

Assessment: The most reassuring commentary of the call on the biggest 2026 headwind. Japan absorbed the worst of the excise shock with share intact, the October step is smaller, and the 2027–2029 structure actually favors the premium leader by opening room to price. The market's most-feared overhang is deflating on schedule, which supports the business case even as it reduces the near-term surprise potential.

5. Combustible Over-Delivery, With a Warning Label

Cigarette volume grew +1.1% and pricing approached +10%, an unusually strong combination that management repeatedly qualified. Full-year pricing is now guided above +7%, but expected to be largely offset by adverse geographic mix; the volume strength is concentrated in Turkey, India, Egypt, and Indonesia, markets with young demographics and little smoke-free presence; and management explicitly does not expect the Q2 magnitude to persist.

Assessment: A clean beat in absolute terms, and a reminder that the combustible engine still has real pricing power and even occasional volume tailwinds. But the segment-mix reality caps how much this flows through: growth skewed to low-revenue-per-unit markets dilutes group mix, which is part of why organic OI growth (+10.7%) trailed the reported figure. Take the cash, don't extrapolate the trajectory.

6. The Guide: Two Beats, Reinvested Rather Than Banked

After two consecutive better-than-expected quarters, management reaffirmed the operational guide rather than raising it, redirecting the upside into the H2 U.S. investment step-up. The headline adjusted-EPS range fell to $8.26–$8.41, but purely on a smaller currency assumption ($0.15, down from $0.20–$0.25); the ex-currency growth range (+7.5% to +9.5%), organic revenue (+5–7%), and organic OI (+7–9%) frames are all unchanged, and the volume outlook was actually nudged up (a sixth straight year of total volume growth, with the cigarette decline narrowed to 2–3% from ~3%).

Assessment: Strategically sound, and consistent with a management team that has spent 15 years investing through the P&L. But for a stock at an all-time high, a reaffirmed (currency-trimmed) guide after two beats is not the beat-and-raise the multiple would need to keep re-rating. It signals confidence in the plan, not upside to it.

7. CFO Transition

This was Emmanuel Babeau's last earnings call as Group CFO; Massimo Andolina, who fielded the Europe question on the call, succeeds him in August. Babeau closed by expressing confidence that PMI "will continue to represent a standout performer within CPG over the coming years."

Assessment: A well-telegraphed, orderly handoff rather than a surprise, and Andolina is an internal promotion already fluent in the strategy. Low risk, but worth logging: a CFO change at the top of a valuation range is a standing item to watch for any shift in guidance philosophy or capital-allocation tone under new stewardship.

8. RBH (Canada) Impairment and the Middle East

Reported EPS carried a non-cash $511M (33-cent) impairment on PMI's deconsolidated Canadian affiliate RBH, after updated five-year projections filed under its court-approved arrangement lowered the investment's fair value (remaining carrying value $51M). Separately, management characterized the Middle East conflict as a minor impact so far (transport, energy, and input costs), with no discernible shift in consumer behavior and no assumed prolonged effect in the forecast.

Assessment: Both are housekeeping. The RBH charge is a non-cash mark on an already-deconsolidated stake and is correctly excluded from adjusted results; the Middle East note is appropriately cautious without being alarmist. Neither changes the operating picture.

Guidance & Outlook

The headline is that the operational plan did not move, again. For the fourth consecutive quarter the ex-currency guide and every underlying frame were reaffirmed, and the only change is a smaller currency assumption that mechanically trims the dollar-EPS range. Some media framed this as PMI "cutting its forecast for the third time this year"; that is the reported-EPS lens, and it is misleading, the currency-neutral trajectory that management and long-term investors actually run the business on is unchanged, and the volume and combustible-pricing sub-guides were raised.

The reinvestment choice is the real story. Two beats did not become a raise because management is deliberately spending the upside on the H2 U.S. push (ZYN Ultra rollout, the "When it Clicks" campaign, distribution, and IQOS ILUMA launch preparation). The guide implies an acceleration in organic operating-income growth in H2, complemented by U.S. momentum, so this is a confident hold, not a defensive one. But it is a hold: after two beats, the year-end number is roughly where it started ex-FX.

Implied H2 shape: H1 adjusted EPS of $4.16 (+9.4% ex-currency) leaves roughly $4.10–$4.25 for H2 to hit the full-year range, with Q3 guided to $2.20–$2.25 (absorbing an 8-cent FX drag and a tough tax comparison). Management expects Q3 HTU shipments around 41 billion against a strong prior-year comp (+15.5%), implying mid-single-digit international smoke-free organic growth in Q3 before a stronger Q4.

Guidance style: Consistent and credible, but no longer a source of positive surprise. PMI is executing a well-telegraphed plan and choosing to invest its outperformance. That is the right long-term call and a poor near-term catalyst for a stock at an all-time high.

Analyst Q&A Highlights

Why the Guide Wasn't Raised After Two Beats

The opening question pressed the central tension of the print: after two better-than-expected quarters, why maintain the full-year underlying guide, and how much flexibility exists in the planned H2 spend. Management tied the decision squarely to the U.S. investment opportunity.

Q: "Despite two quarters of better-than-expected performance and strength, you did maintain your full-year underlying growth guidance. I did just want to verify this is primarily due to your strategic decision to step up investments in the U.S. in the second half, or is there something else we should be mindful of?"
— Bonnie Herzog, Goldman Sachs

A: "The reason why today we're not revising the guidance is indeed the fact that we also are facing a very exciting moment in the U.S. We have an alignment of planets... a much broader portfolio of variants... ZYN Ultra... our new marketing campaign, When it Clicks... The MRTP is almost coming as an icing on the cake. That's really a great moment in the U.S. to accelerate. We're going to go 360."
— Emmanuel Babeau, outgoing Group CFO

Assessment: This is the cleanest confirmation that the "no raise" is a reinvestment choice, not a hidden weakness. It is strategically the right call and consistent with PMI's investment-through-the-P&L DNA. But it also tells the valuation story plainly: the year-end EPS is being held flat ex-currency after two beats, so anyone buying at 23x is paying for a plan, not for upside to it.

ZYN Ultra Early Read and the Low-Nicotine Strategy

A follow-up sought color on the ZYN Ultra rollout, early retailer and consumer feedback, and how the coming lower-nicotine (1.5mg) variant fits the portfolio. Management was deliberately measured on two weeks of data while laying out the strategic logic.

Q: "Just hoping for a little more color on the rollout of ZYN Ultra, early feedback you've been hearing from retailers and consumers, space gains, how incremental do you expect it to be?... how you expect to position [the lower nicotine ZYN] within the broader ZYN portfolio and how incremental that can be."
— Bonnie Herzog, Goldman Sachs

A: "I don't think we want to be overplaying the first two weeks... We have sequential growth. We are growing our share... the first data and first feedback are certainly encouraging. Let's have a bit more weeks... On the low nicotine, we see the 1.5 milligram as particularly relevant to convince smokers to switch... too high in nicotine content can actually create a bad experience and discourage some of them."
— Emmanuel Babeau, outgoing Group CFO

Assessment: The measured tone is the right posture and, for us, the reason to stay patient rather than pay up. The launch is directionally encouraging but two weeks old, and the segmentation logic (Ultra for higher-strength share, 1.5mg for smoker conversion) is coherent. The proof, offtake turning solidly positive, is still a quarter or two out, which is precisely why we downgrade on price rather than chase the reacceleration.

Japan Share Dynamics and October Excise Phasing

A recurring line of questioning probed the Japan progression: category and IQOS growth through the quarter, the TEREA/SENTIA consumable mix, and how the October second excise step phases across Q3 and Q4.

Q: "I wanted to dig in a little bit further on the Japan dynamics during the quarter... any more detail on the share trends within IQOS, the mix between the IQOS consumable portfolio and expectations in the second half, given another excise tax increase in October."
— Matt Smith, Stifel

A: "What we've been experiencing in Japan is in line with our expectations... we have been certainly more impacted on TEREA... there was a very nice SENTIA safety net... We've gone through the worst for us, because this first increase was the worst. The pass-on... is closer to JPY 20 in the second half."
— Emmanuel Babeau, outgoing Group CFO

Assessment: Management answered directly and the substance is reassuring: the tiered portfolio (SENTIA catching down-trading TEREA consumers) worked, share held, and the largest pass-on is behind. This resolves much of the Japan-excise fear that drove the stock to its lows earlier in the year, and it is a real de-risking of the business. It also, again, removes an overhang whose resolution is now largely priced.

Japan Competitive Environment and JT's October Move

A second Japan exchange focused on competitor behavior: whether the promotional intensity of the past year is cycling, and how to read a competitor's below-full-pass-through October price application.

Q: "Could you comment a bit about the competitive environment there? We definitely saw a pickup in promotional activity over the past year from some of your competitors... how are you seeing that evolve in recent months?"
— Eric Serotta, Morgan Stanley

A: "It's probably all hands on deck for every player, given this very strong pass-on in two steps. People are probably no longer playing with... a promotion here... everybody is saying, 'How do I absorb to the best possible of my capacity what is a big increase?'... The fact that we are maintaining our share broadly, 68 versus 69, is just showing that... we stay largely ahead of the competition."
— Emmanuel Babeau, outgoing Group CFO

Assessment: The competitive read is benign: the excise shock has shifted every player from promotion to absorption, and IQOS's leading price position is an advantage when everyone must raise. It supports the durability of Japan share through the digestion, which is a genuine positive for the franchise even if it is not a near-term earnings catalyst.

IQOS Europe Flavor-Ban Recovery and Sustainable Growth

A question on Europe asked what gives management confidence IQOS IMS can reaccelerate after the Poland and Hungary flavor bans, and what a sustainable underlying European growth rate looks like. The incoming CFO took this one.

Q: "What gives you the confidence that IQOS IMS can accelerate again in Europe? And what, in your view, is a sustainable level underlying growth rate in the near term in Europe IQOS?"
— Pallav Mittal, Barclays

A: "If you eliminate the impact... from Poland and Hungary... the underlying growth trend in Europe has not substantially changed... we have already gone through this in a variety of other markets... after the first couple of quarters... then we reestablish the growth trajectory... The second thing is that we have been expanding the portfolio... DELIA... LEVIA... and our playground is, at this point, not only IQOS [VEEV, oral]."
— Massimo Andolina, incoming Group CFO

Assessment: A confident, well-evidenced first showing from the incoming CFO, and the flavor-ban recovery template (Italy is the proof case) is credible. The multi-category framing (IQOS plus VEEV plus oral) is the right strategic answer to regulatory whack-a-mole. It reinforces that the European deceleration is a temporary regulatory artifact, consistent with our read, and offers early comfort on the CFO handoff.

Combustible Volume Momentum: Conservatism or a Real Fade?

A question probed whether the Q2 combustible volume strength was carrying into Q3 and whether the full-year outlook embeds conservatism, given favorable back-half comparisons.

Q: "Given the outperformance that you delivered in volumes this quarter, are you able to provide any color on whether that momentum has maybe sustained over the first part of July... if there may be some conservatism in your full-year volume outlook, or if there are any specific regional headwinds or timing considerations."
— Gerald Pascarelli, Needham & Company

A: "Nothing to flag... what is behind the strength of combustible in Q2 are countries with no smoke-free product presence or limited smoke-free product presence... Turkey, India, Egypt... Indonesia... It doesn't mean that the rest of the year is going to be at the same level. Nevertheless, this is why we have been revising a bit the volume outlook from around minus 3% to 2%-3% decline."
— Emmanuel Babeau, outgoing Group CFO

Assessment: Management declined to extrapolate the strength, which is honest and consistent with the "won't repeat at this magnitude" framing. The upward revision to the volume outlook is a small, credible positive, but the refusal to lean into the momentum confirms that the Q2 combustible print was a high-water mark, not a new baseline. Model the fade.

What They're NOT Saying

1. How much of the H2 U.S. investment step-up flows to the bottom line, and when. Management is explicit that it is spending its two beats on the ZYN launch and IQOS ILUMA prep, but it quantified neither the investment magnitude nor the payback timeline, leaving the H2 margin trajectory and the point at which the U.S. becomes a clean profit contributor undefined.
2. Hard ZYN Ultra offtake numbers. The launch is described as "encouraging" on two weeks of data, but management gave no share, velocity, or distribution figures and cautioned that scanner data does not fully capture effective consumer price, leaving the actual trajectory of the most important U.S. catalyst unverifiable until next quarter.
3. Whether ZYN offtake is actually inflecting or merely stabilizing. "Broadly stable to slightly growing" is a materially better statement than Q1's decelerating +5–6%, but it is still not growth, and management did not distinguish how much of the flat-to-up trend is the new variants versus the base ceasing to erode.
4. The October Japan pass-on decision. Management confirmed the industry step is smaller than April's but pointedly would not disclose its own October price application ("not public yet"), leaving the exact H2 Japan pricing and the Q3-versus-Q4 phasing partly unquantified.
5. Any IQOS ILUMA U.S. timeline. ILUMA was mentioned only as something H2 investment is "preparing for," with no FDA milestone or launch window, consistent with prior quarters treating it as unmodeled optionality rather than a datable catalyst.
6. Capital allocation beyond the dividend. The guide reiterates "no share repurchases" and a ~2.0x leverage target, but with the balance sheet deleveraging and cash flow at ~$13.5B, management said nothing about when buybacks might return or whether M&A (wellness/Aspeya) is on the table.

Market Reaction

• Pre-print setup (July 21 close): $188.04, up ~17.2% year-to-date and ~13.8% over the trailing twelve months (from our ~$165 initiation a year ago), sitting just below the prior 52-week closing high of $192.98. The stock entered the print near its highs and richly owned, the mirror of the oversold, under-owned setup it carried into Q1.
• Reaction session (July 22): Gapped up ~2.1% at the open ($192.03), ran as high as $199.78 intraday (+6.2%), then faded to close at $194.30, up 3.3% (+$6.26), a new all-time closing high.
• Relative move: The S&P 500 was essentially flat (-0.1%) on the session, so PM outperformed the tape by ~3.4 points on an idiosyncratic beat.
• Volume: 7.8M shares versus a 5.2M 30-day average (1.5x), an engaged but not blow-off move.

The tape told the story of the quarter in miniature: a ~5–6% intraday pop on a genuinely large operational beat, then a partial fade as the currency-driven headline-guide trim ("cuts forecast again") crossed the wires and profit-takers met the stock at an all-time high. That the beat still delivered a +3.3% close to a record, against a flat market, confirms the operational strength was real and better-than-feared on the U.S. But the give-back from the intraday highs is the more telling signal for a name at these levels: with expectations now high rather than washed out, even a big beat plus a landed ZYN Ultra plus an MRTP could only produce a few points, because the good news was already substantially in the price.

For the rating, the reaction is the inverse of April's. In April a mixed print produced a +7% rally off a low base because the stock was oversold and the mix beat a low bar. In July a strong print produced a +3.3% close at an all-time high because the bar was high and the stock had already re-rated to reflect it. That asymmetry, big beat, modest reward, at the top of the range, is the textbook signature of a stock that has moved from cheap to fully valued, and it is why we harvest here.

Street Perspective

Debate: Is the U.S./ZYN Inflection Enough to Justify Paying Up at the Highs?

Bull view: The single biggest risk in the story just resolved on schedule. ZYN Ultra shipped, the first-ever pouch MRTP landed, the U.S. recovered sequentially, and management is investing behind a clear "alignment of planets." With the problem child healing and the international engine's underlying pace intact at ~+10% ex-transitory, PM deserves to trade at the high end of its range and can keep compounding into 2027.

Bear view: The inflection is real but priced. Offtake is still only flat-to-slightly-growing, the launch is two weeks old, and the reacceleration proof is a quarter or two away, yet the stock is already at an all-time high and ~23x on a below-algorithm year. The good news is known; the payoff is deferred and being funded by an explicit H2 margin step-up.

Our take: Bear, on price not on business. The ZYN resolution is exactly what we wanted and it de-risks the thesis, which is why we are not more negative. But "great news, fully valued" is a Hold, not an Outperform. We would rather own the reacceleration once it shows in offtake and, ideally, at a better multiple.

Debate: How Much Signal Is in the Combustible Over-Delivery?

Bull view: Growing cigarette volume and near-double-digit pricing prove the combustible engine is more durable than the market credits, funding the smoke-free transition and the dividend with room to spare. Even a partial persistence of this strength is upside to a conservative volume-decline model.

Bear view: Management itself flagged this will not repeat at the same magnitude, the strength is concentrated in low-revenue-per-unit, smoke-free-banned markets that dilute group mix, and the structural cigarette decline is intact. This was a comparison-and-geography high-water mark, not a trend change.

Our take: Bear, and we credit management for saying so. The combustible beat was the lower-quality half of the quarter, real cash but not extrapolable, and its geographic mix is part of why organic OI trailed the reported figure. Take the funding, don't re-rate on it.

Debate: Valuation After the Round-Trip to All-Time Highs

Bull view: At ~23x FY26 and ~21x FY27, a high-single-to-low-double-digit EPS compounder with a growing ~3% yield, a resolving U.S. optionality, and a deflating Japan overhang is not expensive for its quality. Best-in-class CPG compounders trade here and higher.

Bear view: Twenty-three times is the top of PM's own historical range and richer than the ~21.6x at which the same analysts (and this desk) turned cautious in February, on a year still guided below the long-run algorithm, with the core decelerating and the beats reinvested rather than banked.

Our take: Bear, and it is decisive for the rating. We upgraded in April specifically because the ~20% pullback reset the multiple to ~19x; that entire cushion is now gone, and then some. Paying an all-time-high multiple for a franchise whose near-term surprises (Japan resolution, ZYN Ultra, MRTP) have already landed is the opposite of the setup we buy.

Model & Valuation Framework

Valuation: At $194.30 and a 2026 adjusted-EPS midpoint of ~$8.335, PM trades at ~23.3x forward earnings with a ~3.0% dividend yield, versus ~19.4x at our April upgrade and ~21.6x at our February downgrade. This is the richest multiple of the entire coverage period, reached at an all-time-high share price, and the dividend yield has compressed from ~3.6% to ~3.0% as the stock re-rated. On preliminary 2027 EPS of ~$9.35 (algorithm resuming as the U.S. firms), PM trades at ~20.8x, a full multiple for a low-double-digit compounder even crediting the improving U.S.

12-month price target framework: Base case ~$190–205 (roughly 22–23x our ~$8.90 blended NTM EPS, holding the current multiple as the U.S. inflection firms and Japan normalizes), which is essentially where the stock already trades, so the base case embeds little price upside beyond the ~3% yield. Bull case ~$215–230 (24–25x if ZYN Ultra drives a clear U.S. offtake reacceleration and the market prices the 2027 algorithm early). Bear case ~$160–175 (18–19x, a mean-reversion to the middle of PM's range if the multiple compresses as it repeatedly has, or if Japan's October step or the ZYN launch disappoints). The up-to-down skew from $194 is now roughly balanced-to-unfavorable (~+10% bull / ~-13% bear, plus the ~3% yield), which no longer supports Outperform and drives the downgrade to Hold.

Thesis Scorecard Post-Earnings

We grade the standing thesis carried since April. The U.S./ZYN pillar, the one genuine deterioration a quarter ago, improved the most this quarter; the core smoke-free pillars held on an underlying basis but moderated optically; and the valuation bear point re-emerged as the dominant driver, this time of a downgrade.

Overall: Thesis-neutral-to-improved on the business, weakened on the setup. The U.S./ZYN risk that anchored our April conviction-cap is now healing (catalyst delivered), the Japan overhang is deflating on schedule, and the combustible engine over-delivered, all genuine positives that keep us out of anything more negative than Hold. But the two smoke-free pillars moderated optically, and the valuation bear point has re-emerged with force: the stock has round-tripped to an all-time high and the richest multiple of the coverage period, erasing the discount that drove the April upgrade.

Action: Downgrade to Hold from Outperform. This is a valuation and cycle-position call at the top of the range, the mirror of our April upgrade and consistent with a coverage arc in which every rating turn has traded PM's oscillation around an intact, best-in-class transformation. It is not a thesis break, the business is executing and the ZYN risk is resolving, which is exactly why it is a Hold and not lower. Re-upgrade-to-Outperform triggers: a pullback resetting the multiple toward ~19–20x, OR clear evidence ZYN Ultra is driving genuine U.S. offtake reacceleration (offtake turning solidly positive) that would justify paying at the high end. We would consider Underperform only on a real deterioration, an IQOS underlying break, a Japan October demand shock, or a ZYN launch that stalls, none of which is in the data.

Bottom Line: A Great Quarter, a Full Price

Q2 2026 was, on the numbers, the best print of our coverage period. Philip Morris crossed $11 billion in quarterly net revenue for the first time, beat consensus adjusted EPS by a wide margin, expanded margins, and delivered a combustible quarter strong enough that even management sounded slightly surprised. More important for the thesis, the one thing that was genuinely broken a quarter ago got fixed: the U.S. segment recovered sequentially, ZYN Ultra shipped, and the FDA handed ZYN the first-ever nicotine-pouch MRTP. The catalyst we treated in April as optionality we were unwilling to pay full price for arrived, on schedule.

And that is precisely the problem for the stock. We upgraded in April at ~$164 and ~19x because a ~20% pullback had handed us a de-rated franchise with an accelerating international engine and unpriced U.S. optionality. Every leg of that trade has now paid off, the international engine delivered, the U.S. inflected, the Japan overhang deflated, and the market has responded by re-rating PM all the way back to an all-time high at ~23x, a full turn richer than the level at which we downgraded to Hold in February. The discount is gone; the good news is known; the beats are being reinvested rather than banked; and the core, on a reported basis, has moderated.

We are downgrading to Hold. This is not a statement about the business, which is executing about as well as a nicotine-transformation story can, and it is deliberately not Underperform, because the ZYN risk that would have justified real caution is healing rather than worsening. It is a statement about price. Our discipline through this coverage has been simple and, so far, vindicated every quarter: we buy this franchise when the multiple resets and sell it when the multiple runs to the top of its range. At $194 and 23x, at an all-time high, with the near-term surprises already delivered, the multiple has run to the top of its range. We harvest the Outperform, keep the franchise on the buy list, and wait for the next reset.